Availability of lung cancer models that closely mimic human tumors remains a significant gap in cancer research, as tumor cell lines and mouse models may not recapitulate the spectrum of lung cancer heterogeneity seen in patients. We aimed to establish a patient-derived tumor xenograft (PDX) resource from surgically resected non-small cell lung cancer (NSCLC). Fresh tumor tissue from surgical resection was implanted and grown in the subcutaneous pocket of non-obese severe combined immune deficient (NOD SCID) gamma mice. Subsequent passages were in NOD SCID mice. A subset of matched patient and
PDX tumors and non-neoplastic lung tissues were profiled by whole exome sequencing, single nucleotide polymorphism (SNP) and methylation arrays, and phosphotyrosine (pY)-proteome by mass spectrometry. The data were compared to published NSCLC datasets of NSCLC primary and cell lines. 127 stable PDXs were established from 441 lung carcinomas representing all major histological subtypes: 52 adenocarcinomas, 62 squamous cell carcinomas, one adeno-squamous carcinoma, five sarcomatoid carcinomas, five large cell neuroendocrine carcinomas, and two small cell lung cancers. Somatic mutations, gene copy number and expression profiles, and pY-proteome landscape of 36 PDXs showed greater similarity with patient tumors than with established cell lines. Novel somatic mutations on cancer associated genes were identified but only in PDXs, likely due to selective clonal growth in the PDXs that allows detection of these low allelic frequency mutations. The results provide the strongest evidence yet that PDXs established from lung cancers closely mimic the characteristics of patient primary tumors.
Lung cancers are grouped broadly into small cell lung cancer (SCLC, 15%) and non-small cell lung cancer (NSCLC, 85%). Except for very early stage tumors, they collectively lack curative treatments and account for the greatest number of cancer-related deaths worldwide. 1 Recent comprehensive genomic profiling of primary patient tumors belonging to the two most common NSCLC histological classes, 2, 3 adenocarcinomas (AdC) and squamous cell carcinoma (SqCC) has provided new insights into the molecular complexity of these malignancies. Patient tumors are very heterogeneous histologically and genomically, with common cancer driver mutations mostly being restricted to <10% of patients, except for TP53, KRAS and EGFR. 4 This finding suggests that a large number of independent tumor models will be necessary to model the potential diverse mechanisms of lung cancer pathogenesis accurately.
Over decades, multiple tumor models have become available for the study of NSCLC, including cell lines established from patient tumors, [5] [6] [7] GEMMs, 8, 9 and PDXs. 10, 11 However, it remains unclear how well these preclinical tumor models recapitulate patient tumor biology. Some reports suggest that when the molecular profiles of patient tumors are compared to established cell lines, there is substantial genetic divergence between primary lung cancers and cell lines. [12] [13] [14] This observation raises the concern that cellular and biochemical mechanisms unique to culture-adapted cell lines growing on 2-dimensional conditions may not adequately reflect the full spectrum of key processes in patient tumors, and hence, may not accurately model patient responsiveness to cancer therapies. [15] [16] [17] This may contribute to and explain the high failure rates of early phase trials in cancer drug development, 18 as most preclinical drug studies are conducted using established cell lines. Spontaneously formed tumors in GEMMs driven by single or limited number of genes also may be limited in addressing therapeutic responses relevant to patient tumors, 19, 20 as they lack the substantial complexity of genomic alterations associated with patient tumors. Thus, PDX models ultimately may be better preclinical tumor models for oncology drug studies, as they may better mimic the genetic heterogeneity and biological complexity of clinical cancers. 21, 22 We and others have reported the establishment of transplantable NSCLC tumors directly from patients to immunedeficient mice. These PDXs bear close histopathological resemblance to their corresponding primary cancers and they recapitulate patient responses to a number of therapeutic agents. 10, 19, 23, 24 However, it is still unclear to what extent they fully recapitulate the genetic, epigenetic, and signaling mechanisms that collectively drive clinical disease, especially for their matched patient tumors. At a broad level, PDXs harbor similar NSCLC profiles of gene copy number, 25 mRNA 10 and protein, 26 and retain specific "driver" mutations of the matching primary tumors. 10, 11, [25] [26] [27] Here, we now report the high concordance of genome-wide exomic single nucleotide variants (SNVs) and gene copy number variants (CNVs) between 25 PDXs and their matched patient tumors, which comprehensively establishes the ability of PDXs to faithfully recapitulate the genetic mechanisms driving pathobiology of their specific corresponding patient tumors. Furthermore, from a total of 36 PDXs, we use SNV, CNV and gene expression, as well as previously unexamined DNA methylation and phosphotyrosine (pY) proteome profiles to compare similarities between PDXs and publically described NSCLC primary tumors and established cell lines.
Material and Methods

Patient tumors and PDX establishment
The protocol for collection of tumor samples from surgically resected early-stage NSCLC to establish PDXs was approved by The University Health Network Human Research Ethics What's new? Non-small cell lung cancers (NSCLCs) are histologically and genetically diverse, with only a small fraction of patients exhibiting common cancer-driving mutations. While translating that diversity into clinically relevant models has proven difficult, the present study suggests that at least some long-standing challenges may be overcome with patient-derived tumor xenografts (PDXs). PDXs were established by implanting and growing surgically resected human tumor tissue into mice. Subsequent genomic and proteomic profiling revealed fidelity between PDXs and the molecular pathology of matched patient tissues for a subset of models. Compared with cell lines, PDXs more completely recapitulated lung cancer pathogenesis in patients.
and Animal Care Committees. Patient tumor samples were obtained by informed consent. Tumor specimens were divided into small pieces (2 mm), mixed with 10% Matrigel at 48C (Becton Dickinson Biosciences, San Jose, CA), and implanted into the subcutaneous flank tissue of non-obese diabetic severe combined immune deficiency (NOD SCID) gamma mice. All mice were bred in our facility, housed under sterile conditions, and given autoclaved food and water ad libitum. Once tumors reached 1-1.5 cm in diameter, as measured with calipers, mice were euthanized and tumors were implanted/passaged serially into new NOD SCID mice for at least three times to establish model stability. Harvested tumors were divided equally for cryopreservation, quick freeze in liquid nitrogen and preparation of formalin-fixed paraffin-embedded tissue blocks. Comprehensive profiling on PDXs was conducted from early passages 2-4. Authentication of PDX models to their original patient tumors was by comparison of histology reviews and short tandem repeat profiles (AmpFLSTR TM Identifiler TM PCR Amplification Kit, Promega Corp., Madison, WI).
Mutation detection with exome and targeted sequencing
Genomic DNA samples were isolated from 36 PDX tumors, 25 available matched snap-frozen banked primary tumors and 29 matched normal lung tissues. The whole exome was captured using a SureSelect Human 50Mbp kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. For targeted re-sequencing, we prioritized regions with somatic SNVs found by exome sequencing of both PDX and patient tumors and captured those regions using a SureSelect Custom 2Mbp kit. Captured DNA was sequenced using the HiSeq platform (Illumnina, San Diego, CA) and paired-end sequence reads were generated for each sample. Xenome 28 was used to first identify and remove contaminating reads from the mouse stroma for PDX samples by aligning variant reads to the DNA of the NOD/SCID mouse. Basic alignment and sequence quality control was done using Novoalign v3 and Picard v1.78. Mapped exomes were processed by the standard Genome Analysis Toolkit (GATK) for quality control, variant calling, and mutational significance analysis. Somatic mutation calling with matched normal samples was also performed using Strelka v1.0. 29 For cases where there were no matched normal samples, we pooled normal samples from all other patients to identify germline variants and also filtered for SNPs in dbSNP (build 140). Mutations called by both GATK and Strelka were included in the targeted capture. High confidence variants in PDXs included only mutations called by both exome and targeted sequence analysis, or called in only exome sequence analysis but also found in the Catalogue of Somatic mutations in Cancer (COSMIC) database v70.
Copy number alterations
Genomic copy number was measured using the HumanOmni 2.5 BeadChip single nucleotide polymorphism (SNP) array platform (Illumina). The total signal intensity (LogR) and Ballele frequency (BAF) values were reported at each genomic locus that was profiled by the SNP array. The relative copy number gains or losses of genomic regions were identified using the allele-specific copy number analysis of tumors (ASCAT) segmentation algorithm. 30 Each gene was mapped to a genomic region if >50% of the gene overlapped with the region. We reported the average log likelihood ratio (LRR) for each gene, which quantifies the copy number gain in the tumor relative to normal tissue. For instance, a LRR 5 0.5 was considered copy number gain, and LRR 5 20.5 was considered copy number loss (Supporting Information Table S1 ).
Gene expression microarray
RNA from 36 PDX samples was labeled and amplified using the whole genome gene expression DASL HT Assay (Illumina) for partially degraded, FFPE derived RNA. The labeled samples were hybridized onto Human HT-12 V4 BeadChips and processed as per the manufacturer's protocol, and scanned on the iScan (Illumina). The data files were quantified in GenomeStudio Version 2011.1. All the samples passed Illumina sample dependent and independent QC Metrics. Raw intensity data was log2 transformed and quantile normalized by the lumi R package 2.11.1. Batch effects from microarray assays conducted on different dates were adjusted using ComBat (sva R package) with default settings. A list of differentially expressed genes between SqCC and AdC PDXs was identified by analysis of variance (ANOVA) at adjusted p < 0.01. We used Gene Set Enrichment Analysis (GSEA) to test whether the 131 upregulated genes in AdC and 289 genes upregulated in SqCC PDXs were also differentially expressed in patient tumors from the JBR.10 study, GSE14814. 31 The gene expression data from the 36 PDXs and corresponding patient tumors have been deposited in the Gene Expression Omnibus with GSE68929.
DNA methylation chip
The bisulfite-converted DNA samples of tumors and matched patient normal samples were hybridized to the Illumina Infinitium HumanMethylation450 BeadChip and processed as per the manufacturer's protocol. The values M and Beta were background corrected and quantile normalized using the lumi R package 2.11.1. The log ratio between M values between tumor and normal samples defined the somatic methylation score. The methylation score for each gene was an average over all probes 11500 bp and 2500 bp of the transcription start site.
Phosphotyrosine (pY) proteome
Total protein was extracted in urea lysis buffer, reduced and alkylated, and subjected to overnight tryptic digestion as described previously. 26 Peptides were purified by passing through a C-18 column, eluted with 50% acetonitrile and vacuum dried. The pY peptides were enriched using a PTMScanV R Phosphotyrosine Mouse mAb (P-Tyr-100) kit as instructed by the manufacturer's protocol (Cell Signaling Technology, Danvers, MA). The enriched pY peptides were separated on an Easy-Spray column using an instrument with a combination of liquid chromatography and mass spectrometry systems (LC-MS/MS, Thermo Scientific, Odense Denmark). 32 Acquired raw files were analyzed and quantified using MaxQuant software (version 1.3.0.5). 33 The Andromeda probabilistic search engine 34 was used to search peak lists against the Swiss-Prot database (2013 version), with default search parameters as previously described. 35 The proteomics data described in this paper have been deposited to the ProteomeXchange Consortium (http://www.proteomexchange. org) via the PRIDE partner repository with the dataset identifier PXD000809. A detailed method is described in Supporting Information Method S1.
Public datasets
The Cancer Genome Atlas (TCGA) has the most extensive catalogues of mutations, gene copy changes, DNA methylation and gene expression data for the lung cancer subtypes AdC 3,36 and SqCC
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; data for 401 patients were downloaded from cBioportal (July 2014 version). Copy number gains and losses were determined using a LRR cutoff of 60.5. RNA expression data derived from RNAseq by ExpectationMaximization (RSEM) format. The transcriptome of NSCLC was downloaded from GSE14814 dataset. 31 The phosphoproteome for NSCLC of 150 patients and 41 cell lines were acquired from Rikova et al. 37 Broad CCLE cell line mutation, copy number and expression data were downloaded from the October 2012 version of their data portal (http://www.broadinstitute.org/ccle/data/).
Mutations and altered pathways
Gene sets corresponding to pathways found in KEGG and Reactome databases were extracted. Mutations (somatic, wildtype) and copy number alterations (gain, loss, diploid) for each pathway were used as input features for iClusterPlus. 38 The model that maximized Bayesian information criterion was selected for each pathway and the proportion of variation explained was reported. To identify the expression pattern associated with each pathway alteration profile, we used the Random Forests algorithm (R package random Forest) running 1,000 trees on all gene expression profiles and identified the top 100 expression profiles according to their importance scores.
Statistical analyses
The time for disease free survival (DFS) was calculated in years as the difference between the date of relapse or death or last follow-up and the surgery date. Both relapse and death were considered as events. The DFS percentages were calculated utilizing the Kaplan-Meier technique. The survival curves were compared by applying the Log-rank test. The Cox proportional hazards model was used to obtain the hazards ratios both for unadjusted effect as well as for the adjusted effect. The p-values cited in the multivariate analysis were based on the Wald test within the Cox proportional hazards model.
Results
Patient tumors transplanted to mice create stable PDX models A total of 441 serially resected primary lung carcinomas with sufficient excess tumor tissue were implanted into NOD SCID mice and 127 (29%) PDX generated stable growth, which could be passaged serially (Fig. 1a) . Models which failed initial engraftment due to an absence of tumor cells in the tissue fragment used to implant were excluded from analysis. Among 264 NSCLC patients with at least 3-years follow-up, patients whose tumors formed stable PDXs (versus those who did not) showed significantly worse disease-free survival (DFS, HR 5 3.12, 95% CI 52.02-4.83, p < 0.0001) and overall survival (OS, HR 5 4.08, 95% CI 52.16-7.73, p < 0.0001), even after adjusting for sex, stage and differentiation (Figs. 1b-1c ). We excluded neoadjuvant treated patients. Neoadjuvant is not a standard care for lung cancer patients in Canada. Close histological similarities were observed between PDXs and their corresponding patient tumors (Figs.  1d-1k) , as shown in four paired tumors representing adenocarcinoma (AdC, d-e), squamous cell carcinoma (SqCC, f-g), sarcomatoid carcinoma (SC, h-i) and large-cell neuroendocrine carcinoma (LCNEC, j-k). Thirty six (15 AdC, 18 SqCC, two LCNEC and 1 SC) PDX models were comprehensively profiled by five-omics methods: exome, gene copy number, DNA methylation, mRNA expression, and pY proteome, and the matched patient tumor and adjacent normal tissue for a subset of PDXs were also analyzed by some of the platforms (Table 1 and Supporting Information Tables S1 and S2 ).
Genomic fidelity of NSCLC PDXs to their corresponding patient tumors
Given the large number of heterogeneous mutations in NSCLC across patients, PDXs can be a powerful resource to study diverse genetic mechanisms of pathogenesis, provided they faithfully retain the mutation spectrum of the specific patient tumors from which they are derived. To investigate this possibility, we conducted whole exome sequencing of 36 PDXs, and their corresponding 25 patient tumors and 29 normal adjacent tissues, with few patients having insufficient specimen or poor specimen quality for analyses. The exome sequence of PDX tumor cells was additionally enriched over stromal sequence by removing any sequence reads that aligned better to the mouse rather than human genome. Approximately 88-99% of SNVs found in the primary tumor were retained in the matched PDX tumor (109-3373 SNVs/ model) (Supporting Information Fig. S1 ). Of common SNVs, 70% (7,507) were detected at <50% variant allele frequency (VAF) in both paired PDX-patient tumors, and 16% (1,763) had >50% VAF in PDXs, but <50% VAF in primary tumors (Supporting Information Fig. S2 ). In contrast, only 6% of common SNVs (664) had VAFs greater in primary tumors than in PDXs. This enrichment of VAF in PDXs was significant (Chi-squared test p < 2.2 x10 26 ). Focusing on mutations in 395 cancer associated genes from the COSMIC Cancer Gene census, their VAFs were on average 86% higher in PDXs compared to primary tumors. These included 11 actionable mutations in KRAS, BRAF, PIK3CA, and ERBB2 that were detected in the PDXs but were missed in the primary tumor. We verified the somatic SNVs in 31 PDX tumors using targeted deep sequencing (500X) and identified 6,419 unique non-synonymous SNVs, for a 59.4% verification rate (Supporting Information Fig. S3 ). PDXs also recapitulated genome-wide CNVs that are characteristic of their matched patient tumors (Figs. 2a and 2b). For example, between PDXs and patient tumors, common copy number gains were observed on chromosome 7 and 5p of AdCs, while focal amplifications of SOX2 and FGFR1 were shared in several SqCCs. We also observed that the signal intensity from copy number profiling on PDXs was higher than from matched patient tumors. This led to a higher resolution view of CNVs and histologyspecific copy number gains and losses, using the PDXs as compared to patient tumors. A greater signal for copy number estimates were obtained from PDXs as compared to their matched primary tumors, as represented in the models 148 AdC and 77 SqCC (Supporting Information Fig. S4 ). In addition, we observed an increased signal for loss of heterozygosity from the B allele frequencies at loci with known copy alterations.
We also compared the spectrum of genetic alterations in our patient tumors and corresponding PDXs to that observed in NSCLC TCGA patient and cancer cell line encyclopedia (CCLE) data. Of these validated non-synonymous SNVs, only 27% (1,728) have been reported in the COSMIC. The amount of mutation burden in each PDX was comparable to that in primary lung tumors from TCGA (Supporting Information Table S3 ), and was lower than reported in the 70 NSCLC CCLE cell lines. 39 In addition to known mutations, we found several non-synonymous somatic mutations in oncogenes and tumor suppressor genes that have not been reported to date in the COSMIC 40 (Supporting Information Table S4 ).
We found that many broad and focal copy amplifications and deletions were shared between PDX models and patient tumors (Supporting Information Fig. S5 ). Notably, PDX AdC copy number variants (CNVs) were more similar to patient tumors (r 5 0.69) than to AdC cell lines (r 5 0.35) based on the log-R ratio of CNVs. Overall, the number of genes somatically altered (mutation and CNV) in the PDXs was most similar to patient tumors and was lower than in cell lines (Supporting Information Fig. S6 ). These data support our PDXs being appropriate models to study the same type of genetic diversity observed in a larger cohort of NSCLC patients.
The phosphotyrosine (pY)-proteome of PDXs is more similar to patient tumors than to cell lines Alterations in phosphotyrosine (pY) signaling occur widely in cancer, including NSCLC, and contribute to a number of oncogenic mechanisms. 37, 41 Although PDXs recapitulate the genetic alterations associated with primary patient tumors, it has not yet been reported whether they also retain global PTyr patterns. Due to limitations on patient material, we focused on using a liquid chromatography-mass spectrometry (LC-MS) method to detect pY sites on 351 proteins in 31 PDXs, and then compared these pY profiles to published pY datasets of NSCLC cell lines, patient tumors, and corresponding normal lung tissues. 37 Hierarchical and principal components clustering across tyrosine kinases and other subsets of genes in the pY-proteome showed greater similarity between patient and PDX tumors than to cell lines (Fig. 3a) . Furthermore, the PDXs and patient tumors tended to have more variable and lower levels of tyrosine phosphorylation than cell lines (Figs. 3b and 3c ), suggesting cell lines may have an overall greater dependency on high levels of phosphotyrosine signaling by specific kinases.
Transcription and methylation landscapes characterize histological subtypes of NSCLC
Having established the fidelity of PDXs to recapitulate the genetic characteristics and pY signaling patterns of patient tumors, we then performed hierarchical clustering of the 200 most variable DNA methylation sites at gene promoters across 36 PDXs differentiated the tumors according to their histological subtypes (Fig. 4a) . Similar to methylation, hierarchical clustering based on a profile of the 200 most variably expressed genes separated the PDXs according to their paired patient tumor histological subtypes (Fig. 4b) . The PDX DNA methylation or gene expression patterns that correlated with histological subtypes also predicted correctly the subtypes of independent NSCLC patient tumors. Based on the identification of hyper-and hypo-methylated regions along the genome by probing genes and cytosine-phosphate-guanine (CpG) islands, a principal component clustering analysis showed that the methylation profiles of PDXs were more variable than patient tumors from the TCGA dataset (Fig. 4c) ; however, PDX and patient tumors of the same histological subtype clustered closely. Using 131 genes that were differentially up-regulated in AdC PDXs and 289 genes up-regulated in SqCC PDXs (absolute fold change >2, p < 0.001) and applying them to 133 stage I and II NSCLC patient samples (GSE GSE14814), these sets of genes also were upregulated and enriched in the same subtypes of patient tumors (Fig. 4d , p < 0.001). 
Alterations in key cancer drivers and oncogenic pathways
Known oncogenic mutations identified in PDXs included TP53 in 31 (86%), KRAS in 9 (25%), EGFR in 2 (6%) and PIK3CA in 2 (6%) models (Fig. 5a) . The co-occurrence of multiple somatic mutations and copy number aberrations were detected among the PDXs models. Gene sets were identified and associated with specific pathways that contained these alterations. Integrative clustering using iClusterPlus then was applied to the PDX genomic profiles to estimate the proportion of variation explained by alterations in each pathway (Supporting Information Fig. S7a ). Genes regulating cell cycle, including TP53, were altered in all PDX models except one (X207), and integrative clusters based on those alterations explained 50% of the variation in the PDX genomic landscape (Fig. 5b) . The occurrence of alterations in specific gene sets, such as AKT signaling, MAPK signaling and metabolic pathways was correlated with activity in cell signaling processes manifested in both the phospho-proteomic (Supporting Information Fig. S7b ) and mRNA levels (Fig. 5c) . Genomic alterations in the CTLA4 signaling pathway were frequent across PDXs and co-occurred with alterations in cell cycle and AKT signaling pathways. For a subset of these PDXs, we also observed enrichment of genes related to the positive regulation of the immune system.
Discussion
In this study, we have included additional 160 cases to our previous series of 104 cases, and with longer follow-ups, to confirm our previous finding that the ability of NSCLC to grow as xenograft in mice is a strong poor prognostic indication for patient survival. 11 Furthermore, we have utilized five comprehensive omics platforms including exome, gene copy number, DNA methylation, mRNA expression and pYproteome, to characterize 36 of the PDX models. The separation of histological subtypes AdC and SqCC was observed consistently at all levels of the omics profiles. The comparison of the PDX derived data to matched patient tumors, other cohorts of lung cancer patient tumors 2, 3, 36 and established cell lines 37, 39 showed that across gene mutations, copy number alterations and phospho-proteins, there were greater similarities between PDXs to patient tumors than to cell lines. This fidelity and diversity illustrates an advantage of PDX models as preclinical model over cell lines or other in vivo tumor models, including xenografts formed from established cell lines and GEMMs. While GEMMs have an advantage in studying the biology of a single or combination of two genetic abnormalities, their utility is limited to the available models that represent few specific genetic abnormalities and histological types of lung cancers. 42, 43 The high recapitulation of the genomic landscape across NSCLC histological subtypes when PDXs were compared to lung primary tumors 2, 3, 36 as shown in this study, is consistent with omics studies comparing PDXs of breast and colon cancers to their corresponding patient tumors. 44, 45 This contrasts to cell lines, which in previous comparisons to patient tumors have shown low correlation between their point mutation frequencies (p ffi 0:5), and marked differences in their mRNA and copy number profiles. 15, 39 Recently, Gao et al. 22 reported similar results of closer similarities for mutation rates and copy number landscape between PDXs models established across common adult solid cancers, including 42 NSCLC models, and data from primary patient tumors (TCGA) and cell lines (CCLE).
By measuring the VAF, we have shown that a significant proportion of SNVs were detected at higher frequencies in PDXs compared to their corresponding primary tumors. This could be due to higher tumor cellularity in PDXs compared to primary patient tumors, which often have greater stromal and inflammatory cell infiltrates, which are lost during engraftment in immune-deficient mice. 46 Higher VAFs could also result from selective enrichment of clones harboring mutations that favor higher growth rates and/or more aggressive cancer biology. 47 Genomic alterations in cell cycle pathways were the most frequently found changes in PDXs.
While the ability of these PDXs to model histology and the omic profiles is an advantage for their utility as preclinical models, their murine host may hinder specific experimental conditions. Our observation that lower levels of c-MET phosphorylation occurring in PDXs compared to cell lines may be a consequence of the inability of the murine hepatocyte growth factor to activate human c-MET tyrosine function. 48 The NOD SCID strain also lacks an immune system which would prevent the testing of therapeutic strategies that require activation of immune response. Possible alternate murine hosts could include nude or SCID strains which have a greater representation of the immune components, or a humanized mouse host by reconstitution of human hematopoietic stem cells. 49 Nevertheless, we observed a subgroup of PDX tumors with genomic alterations in CTLA4 pathways modulating immune checkpoints that resulted in upregulation of immune system genes. 50 Preclinical models, including PDXs derived directly from patient tumors are emerging as the preferred platform for translational lung cancer research. 39, 44 Some evidence, including studies from our lab, shows that NSCLC PDX models respond similarly to pharmacological agents when compared to their matched patient tumors, 19, 24 indicating that high throughput screening strategy using large number of PDX models may be used pre-clinically to assess population responses to novel therapeutics. 22 Genomics-characterized PDXs models may also enable systematic investigation on the underlying biology and mechanisms of drug response or treatment resistance, identify potential predictive biomarkers for novel drugs, and contribute to the design of early phase clinical trials.
